Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that it has received its State of Washington Radioactive Materials License for the manufacturing of IsoPet®.
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that it has received its State of Washington Radioactive Materials License for the manufacturing of IsoPet®.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.